Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

We already have treatments for depression and PTSD, why do we need more? - Neural Therapeutics

We already have treatments for depression and PTSD, why do we need more? - Neural Therapeutics

Neural Therapeutics Inc. Scientific Advisor Professor David Nutt answers some of the questions raised by his recent presentation on the potentially revolutionary untapped effects of psychedelic medicine.

Today's questions is: We already have approved pharmaceuticals and therapies for the treatment of depression and PTSD, why do we need more?

The presentation itself focused on what Professor Nutt describes as the utility of psychedelic compounds and their potential to transform the treatment of mental illness.

Neural Therapeutics is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no significant treatment is available today.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK